C-Rad Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

C-Rad yıllık ortalama 34.4% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar declining at 1.1% annual. Gelirler growing yılda ortalama 18.6% oranında artmaktadır. C-Rad'in özkaynak karlılığı 17.7% ve net marjı 10.8%'dir.

Anahtar bilgiler

43.1%

Kazanç büyüme oranı

42.2%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	4.3%
Gelir büyüme oranı	19.7%
Özkaynak getirisi	18.7%
Net Marj	11.9%
Sonraki Kazanç Güncellemesi	07 Feb 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

C-Rad nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:24C Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	486	58	259
30 Jun 24	497	54	257
31 Mar 24	458	48	242
31 Dec 23	425	36	229
30 Sep 23	385	24	216
30 Jun 23	357	20	205
31 Mar 23	329	12	195
31 Dec 22	301	7	179
30 Sep 22	280	14	154
30 Jun 22	260	12	143
31 Mar 22	257	21	131
31 Dec 21	261	25	124
30 Sep 21	258	26	120
30 Jun 21	247	25	114
31 Mar 21	230	17	110
31 Dec 20	222	14	109
30 Sep 20	198	-11	110
30 Jun 20	201	-16	115
31 Mar 20	210	-14	120
31 Dec 19	205	-14	117
30 Sep 19	212	23	114
30 Jun 19	203	24	111
31 Mar 19	204	27	106
31 Dec 18	190	21	105
30 Sep 18	174	-2	101
30 Jun 18	161	-4	94
31 Mar 18	141	-10	91
31 Dec 17	133	-11	88
30 Sep 17	118	-16	84
30 Jun 17	108	-23	83
31 Mar 17	90	-28	80
31 Dec 16	83	-31	75
30 Sep 16	74	-33	71
30 Jun 16	70	-32	67
31 Mar 16	73	-27	62
31 Dec 15	73	-21	58
30 Sep 15	73	-20	57
30 Jun 15	66	-16	52
31 Mar 15	62	-8	50
31 Dec 14	57	-7	47
30 Sep 14	56	-5	45
30 Jun 14	59	-4	44
31 Mar 14	52	-17	44
31 Dec 13	49	-21	44

Kaliteli Kazançlar: 24C yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 24C 'nin mevcut net kar marjları (10.8%) geçen yılın (5.7%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 24C şirketinin kazançları son 5 yılda yılda 34.4% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: 24C 'un son bir yıldaki kazanç büyümesi ( 164% ) 5 yıllık ortalamasını (yıllık 34.4% ) aşıyor.

Kazançlar vs. Sektör: 24C geçen yılki kazanç büyümesi ( 164% ) Medical Equipment sektörünün 16.2% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 24C 'nin Özsermaye Getirisi ( 17.7% ) düşük olarak değerlendiriliyor.

C-Rad Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: EPS: kr0.45 (vs kr0.32 in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Recent updates

Third quarter 2024 earnings released: EPS: kr0.45 (vs kr0.32 in 3Q 2023)

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.16 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: kr1.05 (vs kr0.22 in FY 2022)

C-Rad AB (publ) Appoints Mats Thorén as Board Member

New minor risk - Share price stability

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: kr1.36 (vs kr0.22 in FY 2022)

Investor sentiment improves as stock rises 17%

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 23%

New major risk - Share price stability

Investor sentiment improves as stock rises 15%

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings released

New minor risk - Share price stability

Less than half of directors are independent

Full year 2022 earnings released: EPS: kr0.22 (vs kr0.74 in FY 2021)

Full year 2022 earnings released: EPS: kr0.22 (vs kr0.74 in FY 2021)

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

C-Rad AB (publ) Announces CFO Changes

Third quarter 2022 earnings released

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Feb 02, 2024

C-RAD Launches New Updated eDucation Portal as an Online Platform

Second quarter 2022 earnings released

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

First quarter 2022 earnings released

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold €61k worth of stock

Second quarter 2021 earnings released

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin